Top

Published in:

01-12-2011 | Original Article

A Closer Look at Depression and Its Relationship to HIV Antiretroviral Adherence

Authors: Glenn J. Wagner, Ph.D., Kathy Goggin, Ph.D., Robert H. Remien, Ph.D., Marc I. Rosen, M.D., Jane Simoni, Ph.D., David R. Bangsberg, M.D., M.P.H., Honghu Liu, Ph.D., MACH14 Investigators

Published in: Annals of Behavioral Medicine | Issue 3/2011

Abstract

Background

Depression consistently predicts nonadherence to human immunodeficiency virus antiretroviral therapy, but which aspects of depression are most influential are unknown. Such knowledge could inform assessments of adherence readiness and the type of depression treatment to utilize.

Purpose

We examined how depression severity, symptom type, and change over time relate to adherence.

Methods

Microelectronic adherence and self-reported depression data from 1,374 participants across merged studies were examined with cross-sectional and longitudinal analyses. Depression variables included a continuous measure, categorical measure of severity, cognitive and vegetative subscales, and individual symptoms.

Results

At baseline, mean adherence was 69%, and 25% had mild/moderate and 18% had severe depression. In cross-sectional multivariate analyses, continuous depression, cognitive depressive symptoms, and severe depression were associated with lower adherence. In longitudinal analysis, reductions in both continuous and categorical depression predicted increased adherence.

Conclusions

The relationship between global continuous depression and nonadherence was statistically significant, but relatively weak compared to that of cognitive depressive symptoms and severe depression, which appear to pose strong challenges to adherence and call for the need for early detection and treatment of depression.

Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001; 58(8): 721–8.PubMedCrossRef

Orlando M, Burnam MA, Beckman R, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: Results from the HIV Cost and Services Utilization Study. Int J Methods Psychiatr Res. 2002;11:75–82.PubMedCrossRef

Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158:725–730.PubMedCrossRef

DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Inter Med. 2000; 160(14): 2101–7.CrossRef

Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 31: S136–9.PubMedCrossRef

Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care and STDs. 1999; 13(3): 185–97.PubMedCrossRef

Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004; 45(5): 394–402.PubMedCrossRef

Vranceanu AM, Safren SA, Lu M, Coady WM, Skolnik PR, Rogers WH, Wilson IB. The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV. AIDS Patient Care and STDs. 2007; 22: 313–21.CrossRef

Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care. 2004; 16(4): 501–6.PubMedCrossRef

10.

Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care and STDs. 2008; 22: 231–41.CrossRef

11.

Kalichman SC, Graham J, Luke W, Austin J. Perceptions of health care among persons living with HIV/AIDS who are not receiving antiretroviral medications. AIDS Patient Care and STDs. 2002; 16(5): 233–40.PubMedCrossRef

12.

Fairfield KM, Libman H, Davis RB, Eisenberg DM, Phillips RS. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999; 14: 446–8.CrossRef

13.

Bhatia R, Hartman C, Kallen MA, Graham J, Giordano TP. Persons newly diagnosed with HIV infection are at high risk for depression and poor linkage to care: Results from the Steps Study. AIDS Behav. 2011; 15(6):1161–1170PubMedCrossRefPubMedCentral

14.

Hartzell JD, Spooner K, Howard R, Wegner S, Wortmann G. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr. 2007; 44(4): 411–6.PubMedCrossRef

15.

Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000; 23(5): 396–404.PubMedCrossRef

16.

Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999; 21(2): 114–9.PubMed

17.

Wood E, Montaner JS, Bangsberg DR, et al. Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS. 2003; 17(17): 2419–27.PubMedCrossRef

18.

Safren SA, O’Cleirigh CO, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009; 28: 1–10.PubMedCrossRefPubMedCentral

19.

Wagner GJ. Placebo practice trials: the best predictor of adherence readiness for HAART among drug users? HIV Clinical Trials. 2003; 4(4): 269–81.PubMedCrossRef

20.

Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care and STDs. 2002; 16(12): 599–608.PubMedCrossRef

21.

Weidle PJ, Ganea CE, Irwin KL, et al. Adherence to antiretroviral medications in an inner-city population. J Acquir Immune Defic Syndr. 1999; 22(5): 498–502.PubMedCrossRef

22.

Wagner GJ, Ryan GW. Relationship between routinization of daily behaviors and medication adherence in HIV-positive drug users. AIDS Patient Care and STDs. 2004; 18(7): 385–93.PubMedCrossRef

23.

Wing RR, Phelan S, Tate D. The role of adherence in mediating the relationship between depression and health outcomes. J Psychosom Res. 2002; 53(4): 877–81.PubMedCrossRef

24.

Antoni MH, Carrico AW, Duran RE, et al. Randomized clinical trial of cognitive behavioral stress management on human immunodeficiency virus viral load in gay men treated with highly active antiretroviral therapy. Psychosom Med. 2006; 68(1): 143–51.PubMedCrossRef

25.

Yun LW, Maravi M, Kobayashi JS, Barton PL, Davidson AJ. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr. 2005; 38(4): 432–8.PubMedCrossRef

26.

Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med. 2001; 16(9): 625–33.PubMedCrossRefPubMedCentral

27.

Walkup J, Wei W, Sambamoorthi U, Crystal S. Antidepressant treatment and adherence to combination antiretroviral therapy among patients with AIDS and diagnosed depression. Psychiatr Q. 2008; 79(1): 43–53.PubMedCrossRefPubMedCentral

28.

Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008; 47(3): 384–90.PubMedCrossRef

29.

Pearson CR, Simoni JM, Hoff P, Kurth AE, Martin DP. Assessing antiretroviral adherence via electronic drug monitoring and self-report: An examination of key methodological issues. AIDS Behav. 2007; 11:161–73.PubMedCrossRef

30.

Wagner GJ, Kanouse DE, Golinelli D, et al. Cognitive-behavioral intervention to enhance adherence to ART: A randomized controlled trial (CCTG 578). AIDS. 2006; 20:1295–1302.PubMedCrossRef

31.

Finocchario-Kessler S, Catley D, Berkley-Patton J, et al. Baseline predictors of ninety percent or higher antiretroviral therapy adherence in a diverse urban sample: The role of patient autonomy and fatalistic religious beliefs. AIDS Patient Care STDs. 2011;25:103–111.PubMedCrossRefPubMedCentral

32.

Beck AT, Steer RA, Brown GK (1996) BDI-II manual. The Psychological Corporation Harcourt Brace & Company, San Antonio

33.

Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev. 1988; 8: 77–100.CrossRef

34.

Radloff LS. The CES-D scale: A self report depression scale for research in the general population. Applied Psychological Measurement. 1977; 1: 385–401.CrossRef

35.

Derogatis LR. Brief Symptom Inventory 18: Administration, scoring, and procedures manual. Minneapolis, MN: NCS Pearson, Inc. 2001.

36.

Wichers MC, Koek GH, Robaeys G, Praamstra AJ, Maes M. Early increase in vegetative symptoms predicts IFN-α-induced cognitive-depressive changes. Psychological Med. 2005; 35:433–441.CrossRef

37.

Sunnil SB, Gelfand LA, Schmid SP, et al. Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. J Affective Dis. 2008; 110:161–6.CrossRef

38.

Faustman WO, Faull KF, Whiteford HA, Borchert C, Csernansky JG. CSF 5-HIAA, serum cortisol, and age differentially predict vegetative and cognitive symptoms in depression. Biological Psychiatry. 1990; 27:311–8.PubMedCrossRef

39.

Spitznagel MB, Tremont G, Brown LB, Gunstad J. Cognitive reserve and the relationship between depressive symptoms and awareness of deficits in dementia. J Neuropsychiatry Clin Neurosci. 2006; 18:186–190.PubMedCrossRef

40.

Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982; 38: 963–974.PubMedCrossRef

41.

Diggle PJ, Liang KY, Zeger SL. The analysis of longitudinal data. Oxford University Press, Oxford, 1994.

42.

Treisman G, Lyketsos CG, Fishman M, Hanson AL, Rosenblatt A, McHugh PR. Psychiatric care for patients with HIV infection: The varying perspectives. Psychosomatics. 1993; 34(5): 432–9.PubMedCrossRef

43.

Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of protease inhibitors in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001; 2:38–45.PubMedCrossRef

44.

Simoni JM, Safren SA, Manhart LE, et al. Challenges in addressing depression in HIV research: Assessment, cultural context, and methods. AIDS & Behavior. 2011; 15(2):376–388.CrossRef

45.

Tsai AC, Weiser SD, Petersen ML, Ragland K, Kushel MB, Bangsberg DR. A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV. Arch Gen Psychiatry. 2010; 67: 1–9.CrossRef

Title: A Closer Look at Depression and Its Relationship to HIV Antiretroviral Adherence
Authors: Glenn J. Wagner, Ph.D.
Kathy Goggin, Ph.D.
Robert H. Remien, Ph.D.
Marc I. Rosen, M.D.
Jane Simoni, Ph.D.
David R. Bangsberg, M.D., M.P.H.
Honghu Liu, Ph.D.
MACH14 Investigators
Publication date: 01-12-2011
Publisher: Springer US
Published in: Annals of Behavioral Medicine / Issue 3/2011
Print ISSN: 0883-6612
Electronic ISSN: 1532-4796
DOI: https://doi.org/10.1007/s12160-011-9295-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Closer Look at Depression and Its Relationship to HIV Antiretroviral Adherence

Abstract

Background

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2011

A Randomized Trial Comparing the Effect of Two Phone-Based Interventions on Colorectal Cancer Screening Adherence

Depression and Smoking: Mediating Role of Vagal Tone and Inflammation

Fatigue, Depression, Sleep, and Activity During Chemotherapy: Daily and Intraday Variation and Relationships Among Symptom Changes

Evaluation of the Relative Effectiveness of Three HIV Testing Strategies Targeting African American Men Who Have Sex with Men (MSM) in New York City

Treatment-Related Optimism Protects Quality of Life in a Phase II Clinical Trial for Metastatic Renal Cell Carcinoma

Examining the Potential Influence of Diabetes on Depression and Anxiety Symptoms via Multiple Sample Confirmatory Factor Analysis